OncoMatch/Clinical Trials/NCT06759701

Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study

Is NCT06759701 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Tirzepatide for diabetes.

Early Phase 1RecruitingM.D. Anderson Cancer CenterNCT06759701Data as of May 2026

Treatment: Tirzepatide — The goal of this clinical research study is to determine how well a tirzepatide-assisted weight loss program works before a prostatectomy in patients with intermediate risk prostate cancer

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Disease stage

Required: Stage T2C, OR LOWER (NCCN)

Excluded: Stage PT3A OR HIGHER

Grade: Grade group 2Grade group 3 (Gleason)

Clinical T2b-T2c or lower disease; Gleason Grade group 2 or 3 on biopsy; PSA ≤20 ng/mL

Prior therapy

No prior treatment (treatment-naive required)

Cannot have received: androgen deprivation

Any prior androgen deprivation, chemotherapy, surgery, or radiation for PCa

Cannot have received: chemotherapy

Any prior androgen deprivation, chemotherapy, surgery, or radiation for PCa

Cannot have received: surgery

Any prior androgen deprivation, chemotherapy, surgery, or radiation for PCa

Cannot have received: radiation therapy

Any prior androgen deprivation, chemotherapy, surgery, or radiation for PCa

Cannot have received: bariatric surgery

Previous or planned surgical treatment for obesity

Cannot have received: weight loss medication

use of a medication that promotes weight loss within 90 days before screening

Lab requirements

Kidney function

eGFR ≥30 as determined using standard MD Anderson laboratory measures

Liver function

ALT ≤3.0X ULN for the reference range; ALP ≤1.5X ULN for the reference range; total bilirubin ≤1.2X ULN for the reference range (except for cases of known Gilbert's Syndrome); nonalcoholic fatty liver disease allowed if ALT ≤3.0X ULN

Have renal impairment measured as estimated glomerular filtration rate (eGFR) <30...ALT >3.0X ULN...ALP >1.5X ULN...total bilirubin >1.2X ULN (except for cases of known Gilbert's Syndrome)...Participants with nonalcoholic fatty liver disease are eligible to participate in this trial if their ALT level is ≤3.0X the ULN for the reference range

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

The University of Texas M. D. Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify